http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2015115277-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-224 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96452 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 |
| filingDate | 2013-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2015115277-A |
| titleOfInvention | METHOD FOR ASSESSING BLOOD COAGULATION REACTION |
| abstract | 1. A method for evaluating a blood coagulation reaction that is mediated by a substance having blood coagulation factor displacement activity VIII, wherein the method comprises the following steps: (I) adding a blood coagulation initiation reagent including activated blood coagulation factor XI to a blood sample obtained from a subject wherein the sample includes a substance having a blood coagulation factor displacement activity VIII; and (II) measuring the amount of thrombin formed in the blood sample obtained in step (I). 2. The method of claim 1, wherein the substance that has blood coagulation factor VIII substitution activity is a bispecific antibody that binds to blood coagulation factor IX or activated blood coagulation factor IX and to blood coagulation factor X.3. The method of claim 1 or 2, wherein the subject is a patient with a hemorrhagic disease. The method of claim 3, wherein the hemorrhagic disease is a disease caused by decreased or defective activity of blood coagulation factor VIII or activated blood coagulation factor VIII.5. The method of claim 3, wherein the hemorrhagic disease is a disease selected from the group consisting of hemophilia, acquired hemophilia, and von Willebrand disease caused by dysfunction or deficiency of von Willebrand factor (vWF). The method of claim 1, wherein the blood coagulation initiation reagent is a reagent that includes activated blood coagulation factor XI and phospholipid. Blood coagulation initiation reagent for use in the method according to any one of claims. 1-6, which includes activated blood coagulation factor XI.8. The reagent for initiating blood coagulation according to claim 7, which |
| priorityDate | 2012-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.